SANOFI (SNW.DE) Stock Overview
Europe - FRA:SNW - FR0000120578 - Common Stock
SNW.DE Key Statistics, Chart & Performance
The current stock price of SNW.DE is 88.87 EUR. In the past month the price increased by 13.57%. In the past year, price decreased by -11.27%.
SNW.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 51.44 | 678.23B | ||
| 1LLY.MI | ELI LILLY & CO | 51.45 | 678.33B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.82 | 444.61B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.3 | 394.53B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 18.46 | 397.91B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.45 | 248.76B | ||
| 1ROG.MI | ROCHE HOLDING AG-GENUSSCHEIN | 13.92 | 239.54B | ||
| NOT.DE | NOVARTIS AG-REG | 14.94 | 218.05B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 14.99 | 218.75B | ||
| SAN.PA | SANOFI | 11.76 | 216.39B | ||
| 1SAN.MI | SANOFI | 11.8 | 217.12B | ||
| NOV.DE | NOVO NORDISK A/S-B | 13.75 | 204.09B |
Related stock screener links
About SNW.DE
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
SANOFI
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE FR
Employees: 82878
Phone: 33153774000
SANOFI / SNW.DE FAQ
Can you describe the business of SANOFI?
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Can you provide the latest stock price for SANOFI?
The current stock price of SNW.DE is 88.87 EUR. The price increased by 2.8% in the last trading session.
What is the dividend status of SANOFI?
SANOFI (SNW.DE) has a dividend yield of 4.54%. The yearly dividend amount is currently 3.79.
What is the ChartMill rating of SANOFI stock?
SNW.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is SANOFI (SNW.DE) expected to grow?
The Revenue of SANOFI (SNW.DE) is expected to decline by -0.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for SANOFI?
SANOFI (SNW.DE) has a market capitalization of 216.58B EUR. This makes SNW.DE a Mega Cap stock.
What is the next earnings date for SNW stock?
SANOFI (SNW.DE) will report earnings on 2025-10-24, before the market open.
SNW.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SNW.DE. When comparing the yearly performance of all stocks, SNW.DE is a bad performer in the overall market: 82.8% of all stocks are doing better.
SNW.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to SNW.DE. SNW.DE scores excellent on profitability, but there are some minor concerns on its financial health.
SNW.DE Financial Highlights
Over the last trailing twelve months SNW.DE reported a non-GAAP Earnings per Share(EPS) of 7.55. The EPS decreased by -2.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.35% | ||
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| Debt/Equity | 0.21 |
SNW.DE Forecast & Estimates
29 analysts have analysed SNW.DE and the average price target is 109.57 EUR. This implies a price increase of 23.29% is expected in the next year compared to the current price of 88.87.
For the next year, analysts expect an EPS growth of 4.12% and a revenue growth -0.42% for SNW.DE